- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Novartis sheds MorphoSys staff, sites after pelabresib delay | ||
| Do | Vertex weakens after neuropathic pain trial reads out | ||
| Do | Neuralink rival Precision raises $102m, and other financings | ||
| Do | Roche's Parkinson's hope fails second clinical trial | ||
| Do | Novo completes $16.5bn takeover of Catalent | ||
| Do | Ottimo raises $140m for its PD-1/VEGF cancer drug | ||
| Do | MSD makes its obesity move with $2bn Hansoh deal | ||
| Do | Mesoblast finally pushes GvHD cell therapy over finish line | ||
| Mi | Novo Holdings leads $100m round for novel painkiller biotech | ||
| Mi | Sensorion encouraged by deafness gene therapy data | ||
| Mi | Lilly's Alzheimer's drug Kisunla is cleared in China | ||
| Mi | MSD eyes June verdict for paediatric RSV antibody | ||
| Mi | UnitedHealth killing suspect gets first-degree murder charge | ||
| Di | Teva, Sanofi score well with anti-TL1A drug in IBD test | ||
| Di | Study backs Closed Loop's drug+digital blood pressure plan | ||
| Di | End of the line for MSD's TIGIT, LAG-3 cancer drugs | ||
| Di | FDA dents J&J's blockbuster hopes for Rybrevant | ||
| Di | PBM reform looms in end-of-year US legislation package | ||
| Mo | FDA clears Neurocrine drug for rare adrenal disorder | ||
| Mo | Novo sets aside $1.2bn for rare diseases plant | ||
| Mo | Galderma adds new indication for blockbuster hope Nemluvio | ||
| Mo | New drugs 'benefit patients, but maybe not populations' | ||
| Mo | AbbVie adds psoriasis med with Nimble takeover | ||
| 13.12. | ICER identifies new crop of 'unsupported' drug price rises | ||
| 13.12. | Top podcaster spread health misinformation, claims BBC probe |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
